This study looks at combining two medicines, **elranatamab** (a shot) and **iberdomide** (a pill), for people with a type of blood cancer called multiple myeloma. Multiple myeloma affects **plasma cells**, which are white blood cells that make antibodies to fight infections. The study has two parts. The first part checks how safe and tolerable the combination is, and the second part decides the proper dosage for patients whose cancer has come back or doesn’t respond to treatment.
Participants will take the medicines in 28-day cycles. During each cycle, elranatamab is given as an injection under the skin, and iberdomide is taken by mouth for 21 days. The study continues until participants’ cancer progresses, they experience serious side effects, or they choose to stop.
**Key Points**:
- **Study Duration**: Medicine cycles last 28 days, with continuous monitoring.
- **Participation**: Participants must have had 1-4 previous treatments including certain drug types.
- **Risks**: Side effects are monitored; participants can leave if side effects are too severe.
This research aims to determine if the combination is safe and effective for treating multiple myeloma.
How understandable was the trial content above?
Hard to understand
Easy to understand